Abstract
Autologous peripheral blood stem celt transplantation (auto-PBSCT) has been increasingly used in the treatment of malignant disease, and has begun to replace autologous bone marrow transplantation (autoBMT) because of rapid engraftment and low transplant-related mortality. Some clinical studies have demonstrated the safety and efficacy of high-dose chemotherapy followed by auto-PBSCT for the treatment of acute myelogenous leukemia, malignant lymphoma, multiple myeloma, and solid tumor such as breast cancer. Recently, allogeneic PBSCT (allo-PBSCT) s being evaluated as an alternative to alloBMT. Recent studies suggest that allo-PBSCT results in more rapid engraftment without an apparent increase in acute graft-versus-host disease (aGVHD) as compared to bone marrow, but further studies will be required to assess its efficacy.
| Original language | English |
|---|---|
| Pages (from-to) | 360-369 |
| Number of pages | 10 |
| Journal | Biotherapy |
| Volume | 12 |
| Issue number | 3 |
| Publication status | Published - Jan 1 1998 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cite this
Peripheral blood stem cell transplantation - Current status and issues -. / Takenaka, Katsuto; Harada, M.
In: Biotherapy, Vol. 12, No. 3, 01.01.1998, p. 360-369.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Peripheral blood stem cell transplantation - Current status and issues -
AU - Takenaka, Katsuto
AU - Harada, M.
PY - 1998/1/1
Y1 - 1998/1/1
N2 - Autologous peripheral blood stem celt transplantation (auto-PBSCT) has been increasingly used in the treatment of malignant disease, and has begun to replace autologous bone marrow transplantation (autoBMT) because of rapid engraftment and low transplant-related mortality. Some clinical studies have demonstrated the safety and efficacy of high-dose chemotherapy followed by auto-PBSCT for the treatment of acute myelogenous leukemia, malignant lymphoma, multiple myeloma, and solid tumor such as breast cancer. Recently, allogeneic PBSCT (allo-PBSCT) s being evaluated as an alternative to alloBMT. Recent studies suggest that allo-PBSCT results in more rapid engraftment without an apparent increase in acute graft-versus-host disease (aGVHD) as compared to bone marrow, but further studies will be required to assess its efficacy.
AB - Autologous peripheral blood stem celt transplantation (auto-PBSCT) has been increasingly used in the treatment of malignant disease, and has begun to replace autologous bone marrow transplantation (autoBMT) because of rapid engraftment and low transplant-related mortality. Some clinical studies have demonstrated the safety and efficacy of high-dose chemotherapy followed by auto-PBSCT for the treatment of acute myelogenous leukemia, malignant lymphoma, multiple myeloma, and solid tumor such as breast cancer. Recently, allogeneic PBSCT (allo-PBSCT) s being evaluated as an alternative to alloBMT. Recent studies suggest that allo-PBSCT results in more rapid engraftment without an apparent increase in acute graft-versus-host disease (aGVHD) as compared to bone marrow, but further studies will be required to assess its efficacy.
UR - http://www.scopus.com/inward/record.url?scp=0031947202&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031947202&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0031947202
VL - 12
SP - 360
EP - 369
JO - Biotherapy
JF - Biotherapy
SN - 0914-2223
IS - 3
ER -